Entries by Mark DaFonseca

CoreRx, Inc. names Deborah Wild as Executive Chairwoman of the Board

CLEARWATER, FL, June 1, 2021, CoreRx, Inc., is pleased to announce the appointment of Deborah Wild as the Executive Chairwoman of the Board.  Deborah is an accomplished C-Suite executive bringing a wealth of pharmaceutical and biologics experience, having held numerous senior leadership and management positions across manufacturing, supply chain, quality, and regulatory affairs.  Her impressive […]

CoreRx Acquires Nucleo Life Sciences

Acquisition Creates Unparalleled East / West Coast Development Services Presence in the US CLEARWATER, FL, May 24, 2021, CoreRx, Inc. announced today the acquisition of Nucleo Life Sciences, a boutique CDMO based in San Rafael, California. Nucleo complements CoreRx’s development services and capabilities and provides a local site on the US West Coast for development […]

CoreRx Inc. receives approval for Schedule I controlled drug manufacture

Approval now extends ability to develop and manufacture all scheduled drug classifications CLEARWATER, FL, April 30, 2021, CoreRx, Inc., is pleased to announce that they have received approval from the Federal Drug Enforcement Agency (DEA) to develop and manufacture Schedule I controlled substances in their facilities. Schedule I substances are “considered the most dangerous class […]